Pfizer wins fast-track status for breast cancer drug palbociclib

04/12/2013 | PharmaTimes (U.K.)

The FDA granted breakthrough therapy designation to Pfizer's palbociclib as possible treatment for breast cancer patients. The decision was based on preliminary midstage trial results showing palbociclib's efficacy in improving median progression free survival in patients, in combination with letrozole.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA